Metabolic basis for the evolution of a common pathogenic Pseudomonas aeruginosa variant

  1. Dallas L Mould
  2. Mirjana Stevanovic
  3. Alix Ashare
  4. Daniel Schultz
  5. Deborah A Hogan  Is a corresponding author
  1. Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, United States
  2. Department of Medicine, Dartmouth-Hitchock Medical Center, United States

Abstract

Microbes frequently evolve in reproducible ways. Here, we show that differences in specific metabolic regulation rather than inter-strain interactions explain the frequent presence of lasR loss-of-function (LOF) mutations in the bacterial pathogen Pseudomonas aeruginosa. While LasR contributes to virulence through its role in quorum sensing, lasR mutants have been associated with more severe disease. A model based on the intrinsic growth kinetics for a wild type strain and its LasR derivative, in combination with an experimental evolution based genetic screen and further genetics analyses, indicated that differences in metabolism were sufficient to explain the rise of these common mutant types. The evolution of LasR lineages in laboratory and clinical isolates depended on activity of the two-component system CbrAB, which modulates substrate prioritization through the catabolite repression control pathway. LasR lineages frequently arise in cystic fibrosis lung infections and their detection correlates with disease severity. Our analysis of bronchoalveolar lavage fluid metabolomes identified compounds that negatively correlate with lung function, and we show that these compounds support enhanced growth of LasR cells in a CbrB-controlled manner. We propose that in vivo metabolomes contribute to pathogen evolution, which may influence the progression of disease and its treatment.

Editor's evaluation

This study aimed to identify the genetic foundation favoring selection of lasR mutants in laboratory and clinical isolates from persons with CF. They selected these mutants using a predictable and quantitative framework of evolution experiments and then identified their genetic underpinnings by a suppressor screen. The role of cbrAB as a key intermediate is important and ties together several reports of nutrient-dependent advantages of lasR, including those that may explain their adaptation to conditions found in the CF airway.

https://doi.org/10.7554/eLife.76555.sa0

eLife digest

Bacteria can evolve quickly, a skill that proves useful in ever-changing environments. For example, individuals in many bacterial species can start to work together under certain circumstances; this ability is underpinned by a system called quorum sensing, which allows cells to detect nearby conspecifics. However, species of harmful bacteria often lose their quorum sensing abilities when they infect humans. This is the case for Pseudomonas aeruginosa, which normally lives in the soil but can also cause deadly conditions, especially in hospital settings.

Patients often carry P. aeruginosa with mutations that disable the quorum-sensing signal receptor LasR, a molecular actor that can switch on many other genes in a cell. People who are infected with P. aeruginosa strains carrying a damaged version of the lasR gene are typically more ill and less likely to recover. Why this is the case – and in fact, why genes associated with quorum sensing often lose function during infection – is still unclear.

To investigate this question, Mould et al. used laboratory evolution experiments and computer models of P. aeruginosa growth to understand how lasR mutant cells evolve. Differences in growth rates and ways to use resources (rather than changes in cell-to-cell interactions) best explained why lasR mutants become more successful. Further experiments narrowed down the molecular cascade required for the rise of lasR mutants, identifying a pathway that regulates how P. aeruginosa switches between different nutrient sources.

This work reveals a new connection between quorum sensing genes and nutrient regulation in bacterial cells. Loss of functional LasR changes the way that cells use nutrients, and thus will reshape how they interact with host cells and other bacteria. This insight could lead to better ways to predict the outcomes of bacterial infections and how to best treat them.

Introduction

Quorum sensing (QS) is a mechanism of microbial communication that regulates the expression of a suite of genes in response to diffusible autoinducers in a population (Schuster and Greenberg, 2007; Schuster et al., 2003). Despite the importance of cell-cell communication for virulence (Rumbaugh et al., 2009) and high conservation across divergent phylogenies, key QS regulators in diverse species, such as Pseudomonas aeruginosa, Vibrio cholerae, and Staphylococcus aureus, frequently lose function (Mould and Hogan, 2021), due to recent missense and nonsense mutations, indels, or genome rearrangements. These paradoxical findings suggest that there may be connections between QS and other key physiological pathways that have yet to be revealed.

In P. aeruginosa, many isolates from humans, plants, and water sources have loss-of-function mutations in the gene encoding the transcription factor LasR (Groleau et al., 2022; O’Connor et al., 2021), which is central to an interconnected QS network (Schuster et al., 2003). LasR isolates have been repeatedly observed in P. aeruginosa lung infections in people with cystic fibrosis (pwCF) (Smith et al., 2006), and LasR isolate detection is associated with more rapid lung function decline and more inflammation than in comparator populations (Hoffman et al., 2009; LaFayette et al., 2015). In a clinical study of acute corneal infections (Hammond et al., 2016), LasR strains also correlated with more damage and worse outcomes.

Multiple studies contribute to our understanding of the physiologies and social interactions that impact LasR LOF mutant fitness. Several studies provide evidence in support of the model that LasR strains are ‘social cheaters’ that reap the benefits of shared goods secreted by neighboring wild-type cells without incurring the metabolic costs (Sandoz et al., 2007). In this case, LasR strains grow better when the wild type is in the majority, and crash when a critical threshold of LasR cells is surpassed due to insufficient wild-type support (West et al., 2006). The extent of lasR mutant ‘cheating’ depends on the cost-benefit difference, and multiple shared goods, including siderophores, must be considered (Ozkaya et al., 2018). To combat the rise of cheaters, P. aeruginosa produces products such as hydrogen cyanide, rhamnolipids, or pyocyanin that inhibit the growth of quorum sensing mutants through a process known as ‘policing’ (Castañeda-Tamez et al., 2018; García-Contreras et al., 2020; Wang et al., 2015). There is evidence that the presence of LasR subpopulations may be beneficial (García-Contreras and Loarca, 2020) and lead to emergent properties including metabolite-driven interactions between wild type and lasR mutants that provoke the production of QS-controlled factors by the lasR mutant to levels greater than in wild-type monocultures (Mould et al., 2020). In addition to the interactions between LasR+ and LasR cells that influence the fitness and behavior of LasR strains described above, there are important intrinsic characteristics of LasR strains including increased Anr-regulated microoxic fitness (Clay et al., 2020), resistance to alkaline pH in aerobic conditions (Heurlier et al., 2005), and altered metabolism (D’Argenio et al., 2007). The metabolic advantages associated with LasR strains include growth on individual amino acids (D’Argenio et al., 2007). The numerous differences described between LasR+ and LasR strains indicate that an understanding of the factors that drive the rise and persistence of lasR mutants may be complex and are not yet well understood. While it is clear that there are many ways in which lasR LOF mutants differ from their LasR +progenitors, a common trait that promotes the rise of LasR strains in diverse environments, even in rich and minimal laboratory media (Heurlier et al., 2005; Scribner et al., 2022; O Brien et al., 2017; Luján et al., 2007; Qi et al., 2016; Robitaille et al., 2020; Sandoz et al., 2007; Wong et al., 2012; Yan et al., 2018), has not been established.

Here, we use mathematical modeling, experimental evolution-based genetic screens, phenotype profiling, and whole-genome sequencing of evolved communities in different backgrounds to understand the rise of LasR strains over only a few serial passages. We identified the CbrAB pathway as the strongest contributor to the rise of lasR LOF mutants, and our findings were not specific to strain background or medium. LasR strains are more commonly detected in samples from individuals with more severe CF lung disease (Smith et al., 2006). Analysis of bronchoalveolar lavage samples from pwCF and non-CF comparators identified several compounds that were higher in pwCF and that inversely correlated with lung function. LasR strains showed improved growth on the majority of these compounds, many of which were amino acids, and epistasis analysis confirmed that the improved growth was due to altered activity of the CbrB-CrcZ-Crc pathway.

Results

Mathematical model built from monoculture growth data predicts the observed rise of lasR loss-of-function mutants

Our previous work on microbial interactions involving LasR+ and LasR P. aeruginosa revealed subtle differences in growth kinetics (Mould et al., 2020). In monoculture, P. aeruginosa strain PA14 ∆lasR had no lag phase, while the wild type had a lag phase of 1 h (Figure 1A for summary data and Figure 1—figure supplement 1 for growth curve). Furthermore, consistent with work by others, the ∆lasR strain had a lower growth rate (García-Contreras et al., 2020) but a 1.5-fold higher yield in LB (Diggle et al., 2007). We found no differences in death rate resulting from elevated culture pH (as has previously been reported in low oxygen conditions [Heurlier et al., 2005]) or the onset of death phase relative to PA14 wild type under these conditions (Figure 1—figure supplement 1).

Figure 1 with 2 supplements see all
Mathematical model built from monoculture growth data is sufficient to explain the rise of LasR loss-of-function strains.

(A) Predicted densities (left y-axis) of mathematical model shown for wild type (WT, dashed line) and LasR (solid line) strains. Predicted percentages (right y-axis) of LasR (beige fill) and LasR+ (green fill) strains over the course of evolution regime in LB with passage (Pn) every 2 days. Table shows experimentally measured growth parameters used to create the model as obtained for strains PA14 WT and ∆lasR grown in 5 mL LB cultures on a roller drum. (B) Percentage of LasR phenotypes observed in n ≥ 4 independent evolution experiments in LB. Different shapes represent independent experiments, and same shapes represent technical replicates. A representative image of the smooth LasR+ and sheen LasR colonies from Day 6 is shown. (C) lasR alleles detected in the population at Day 4 (4 d) and Day 6 (6 d) by PoolSeq within the lasR coding sequence, which includes the autoinducer binding and DNA binding domains, for a representative experiment (diamond symbols, in B). The percentages of each allele and the sum (i.e. % total) is indicated for each replicate culture. Each color represents a different allele. (D) LasR regulates the production of its cognate autoinducer 3OC12HSL via direct transcriptional control of the gene encoding the LasI synthase. LasI-produced autoinducer activity of evolved pools from a representative experiment (diamond symbols, in B) at days 2 and 6. Activity is presented as a percentage of that produced by unevolved WT monocultures. The levels produced by the engineered ∆lasR control strain is shown for reference (dotted line). **, p = 0.0015 as determined by two-tailed, upaired t-test. (E) Comparison of predicted (dashed line) and observed (solid line) outcomes of competition assays initiated at different initial ratios for which a constitutively tagged WT (att::lacZ) was competed against ∆lasR (beige, gray line) or WT (control, green) competitors for 6 h (final) in planktonic LB cultures with 95% confidence intervals shown for best fit line (quadratic).

We built a mathematical model of strain competition exclusively from experimentally determined monoculture growth parameters to predict the relative changes in wild type and LasR cell numbers when grown on a common pool of growth substrates in order to determine how differences in growth kinetics alone would impact the rise of LasR lineages (Figure 1A). We modeled cell density (Figure 1A -left y-axis) and the percentage of LasR cells (Figure 1A -right y-axis) assuming a shared nutrient source and a passage every 48 hr which is a regime used previously to study the selection for LasR cells (Heurlier et al., 2005). Based on the mutation frequency of the P. aeruginosa strain PA14 (0.52 × 10−3 per genome per generation) (Dettman et al., 2016) and the size of the lasR gene (720 bp) relative to the genome (~ 6 Mbp), we approximate 50 lasR alleles with nucleotide changes would be present in a dense culture ( ~ 108 cells), a fraction of which would lead to a LasR phenotype. With the assumption of 2 to 20 LasR cells per inoculum (t = 0, ~ 105 cells), the model predicted that ~ 20% of the population would consist of LasR cells by Day 4, with increased percentages of ~ 40% and ~ 80% by Days 6 and 8, respectively (Figure 1A). Only minor differences in percentages resulted from changes in the initial LasR population.

We compared the model output to experimental data gathered with the same growth conditions and evolution regime. A single PA14 wild-type colony was used to inoculate a 5 mL culture of LB, which was grown to saturation and then used to inoculate three 5 mL LB cultures which were then passaged independently. Results from all three replicates from four independent experiments are shown. The percent of cells with LOF phenotypes were enumerated by plating and determining the percent of colonies with the characteristic ‘sheen’ colony morphology of LasR cells that result from accumulation of 4-hydroxy-2-heptylquinoline (HHQ) (Figure 1B; D’Argenio et al., 2007). In all four independent experiments, the percentage of colonies with the LasR phenotype rose from undetectable levels to an average of ~ 80% over the course of 8 days (Figure 1B). To validate the use of colony sheen as an indicator of the LasR genotype, we evaluated ≥ 90 isolates with the characteristic LasR colony morphology for other phenotypes associated with LOF: low production of proteases and autoinducers (3OC12HSL and C4HSL). Most of the predicted LasR isolates (~ 90%) had phenotypes that mirrored those of the PA14 ∆lasR strain, and not wild type (Figure 1—figure supplement 2). Consistent with other studies (Feltner et al., 2016), approximately 15% of the cells with other LasR phenotypes produced high levels of C4HSL even though 3OC12HSL production was low.

The percentage of LasR cells predicted by the model matched the frequency of lasR alleles in genome sequence data from pools of colonies obtained from Day 4 and 6 cultures of a representative experiment (diamond symbols in Figure 1B). Across replicates, six non-synonymous mutations were identified in lasR in the regions corresponding to the LasR autoinducer binding (∆36–38, W60R, and L130P) and DNA binding domains (E183G, A231V, and N233Y) (Figure 1C and Supplementary file 1), which are important for function (Feltner et al., 2016). No synonymous mutations in lasR were detected. Two mutations (∆36–38 and L130P) were present in all three replicate cultures at Day 4 and thus were likely present in the initial inoculum. In replicate A, two additional mutations in lasR (E183G and A231V) were identified at Day 6; the LasR A231V substitution has been extensively characterized as a loss-of-function mutation through phenotyping and genetic complementation (Luján et al., 2007; Qi et al., 2016). The percentage of lasR mutants in the evolved population detected by sequencing at Day 4 (22.2 ± 6.0% s.d.) and Day 6 (48.5 ± 4.9% s.d.) (Figure 1C) closely resembled the percentage of LasR strains predicted by the model (~ 20% and ~ 50%, respectively) (Figure 1A). The increased frequency of cells with the allele encoding the L130P substitution (McCready et al., 2019) between Day 4 and Day 6, with 13.1%, 24.6%, and 41.4% increases in replicate cultures, suggests strong selection for this particular variant or the presence of an additional mutation(s) in this background. In support of the significant increases in LasR subpopulations, the evolved cultures themselves had lower levels of the LasR-regulated autoinducer 3OC12HSL; by Day 2, culture 3OC12HSL levels were ~ 30% lower than a non-evolved wild-type culture, and showed a ~ 90% reduction by Day 6 (Figure 1D).

To further test the predictive power of our model for the rise of LasR lineages, we initiated cultures with different ratios of a constitutively tagged wild type (att::lacZ) against untagged wild-type or ∆lasR mutant competitors. A control assay demonstrated that the ratios of tagged and untagged wild type were unchanged over the course of growth, as indicated previously under distinct conditions (Clay et al., 2020; Mould et al., 2020). When the ∆lasR competitor was cultured with the tagged wild type for 6 hr, the percentage of ∆lasR mutant cells in the total population increased regardless of the initial percentage of ∆lasR (1–85%) at the time of inoculation (Figure 1E). The model successfully predicted that ∆lasR would outcompete the wild type over this range which is consistent with differential growth kinetics playing a major role (Figure 1E -dotted line). No ∆lasR advantage would be observed when it is at high initial percentages if its advantage was solely due to exploitation of common goods, as is observed when WT and ∆lasR are co-cultured on a substrate that requires WT protease production (Sandoz et al., 2007). There were differences between the best fit lines for the actual and predicted data that could be due to a variety of factors including measurement error or biological interactions between WT and ∆lasR strains (e.g policing Castañeda-Tamez et al., 2018; Wang et al., 2015).

Activity of CbrAB, the two-component system that regulates carbon utilization, is required for the rise of LasR strains

To test which genes or pathways were required to promote the selection of LasR cells, we applied reverse genetics to experimental evolution. In P. aeruginosa, the sensor kinases of two-component systems, encoded throughout the genome, respond to a variety of diverse internal and environmental cues, such as nutrient limitation or stresses, that may be relevant to differential fitness (Rodrigue et al., 2000; Wang et al., 2021). Using a library of 63 sensor kinase deletion mutants (Wang et al., 2021), we screened each mutant for the rise of LasR phenotypes in triplicate in a 96-well plate format (Figure 2—figure supplement 1). In the primary microtiter dish-based screen, in which the investigators were blind to mutant strain identity, five gene knock-outs (∆cbrA,gacS,fleS, ∆PA14_64580, and ∆PA14_10770) showed no detectable ‘sheen’ colony phenotypes characteristic of LasR strains in any of the three replicates (Figure 2—figure supplement 1 & Supplementary file 2). In a secondary screen of these five mutants in five mL cultures, only the ∆cbrA mutant (Figure 2A) did not evolve LasR phenotypes after serial passage; the other four mutants all had significant subpopulations with LasR phenotypes by Day 6 (Figure 2—figure supplement 2A). LasR strains rose with a similar frequency as in the wild type progenitor when evolution experiments were initiated with strains lacking the regulator Anr, important for LasR microoxic fitness, or the regulator RhlR, important for lasR mutant policing (Chen et al., 2019; Clay et al., 2020) suggesting that these regulators were not major contributors to fitness under these conditions (Figure 2—figure supplement 2B).

Figure 2 with 2 supplements see all
Activity of the carbon catabolite repression system is required for LasR selection in LB.

(A) The percentage of colonies with LasR phenotypes enumerated over the course of evolution for ∆cbrA or ∆cbrB mutants (purple triangle and square, respectively) in strains PA14 or a LasR+ cystic fibrosis isolate (DH2417) relative to ‘wild-type‘ comparators. PA14 WT strain data is the same as in Figure 1B (n ≥ 3). Statistical significance was determined between percent LasR phenotypes in CbrA/B + and cbrA/B mutant pools each day via Two-Way ANOVA with Dunnet’s multiple hypothesis correction. For all panels: *, p < 0.05; **, p < 0.005; ***, p < 0.0005; ****, p < 0.0001. (B) The carbon catabolite repression system promotes the preferential consumption of succinate (and other preferred substrates) through the two-component system CbrAB. CbrA activates its response regulator CbrB which directly induces expression of the small RNA crcZ. crcZ sequesters Crc thereby allowing translation of the target gene to occur. Often the target gene enables the utilization of specific (i.e. less preferred) substrates. In a catabolite repressed state, such as when succinate is present, Crc binds to target mRNA with the RNA binding protein Hfq and blocks translation. CbrB protein levels are higher in strains lacking LasR function, but the mechanism linking these pathways is uncharacterized. (C) Percent total mutant alleles in lasR (pink bar), fleR (gray bar), crc (light blue bar), and hfq (darker blue bar) in a representative experiment (Figure 1B, diamond symbols) for PA14 wild type, ∆cbrA, ∆cbrB evolved populations sequenced on Day 4 (white filled symbol) and six (gray filled symbol). Representative image of the larger colony morphologies observed in the evolved pools from CbrA/B- deficient strains (∆cbrA shown) above. (D) Crc represses amiE encoding an amidase that can turnover the fluoroacetamide (FAA) protoxin to fluoroacetate (FA) mediating cell death. In the presence of succinate, cells with functional Crc survive in the presence of FAA. PA14 WT, PA14 ∆cbrA, PA14 ∆cbrB, and DH2417 WT strains were included as controls. The ∆cbrA and ∆cbrB parental strains used for the evolution experiments and representative colonies that emerged with a larger colony size in these backgrounds were patched (or struck out) onto succinate containing plates in the absence and presence of the FAA protoxin. (E) crcZ expression of PA14 ∆lasR in LB (white bar) and LB with 40 mM succinate (blue bar) measured by qRT-PCR and plotted relative to expression of ∆lasR in LB (n = 4). Inset shows representative image of ∆lasR, ∆lasR∆crc, and ∆lasR∆crc +crc grown on succinate containing plates in the absence and presence of FAA. (F) Percentage of colonies with LasR phenotypes observed in evolution experiment initiated with strain PA14 WT in LB supplemented with 40 mM succinate (n = 6). P-values of 0.007 and 0.005 for comparison of ∆lasR∆cbrB (LB) and ∆lasR (LB +succinate) relative to ∆lasR grown in LB as determined by ordinary one-way ANOVA with Dunnett’s multiple comparison test.

CbrA, through its regulation of the response regulator CbrB, (D’Argenio et al., 2007; Sonnleitner et al., 2009), controls P. aeruginosa preferential catabolism of certain carbon sources, such as succinate, over others (e.g. amino acids) through a process referred to as catabolite repression. In support of the finding that CbrA was essential for the evolution of LasR lineages, the ∆cbrB mutant also showed a striking and significant reduction in LasR phenotypes over the course of 8 days (Figure 2A). Additionally, evolution experiments in a LasR+ cystic fibrosis clinical isolate (DH2417) showed a similar rise in LasR phenotypes over the course of evolution, which was delayed and reduced in a ∆cbrB derivative (Figure 2A). CbrAB-controlled catabolite repression is regulated by Crc, in complex with the RNA-binding protein Hfq, which together repress the translation of target mRNAs involved in the transport and catabolism of less preferred substrates (Figure 2B; Sonnleitner et al., 2017). Crc activity is down regulated by the small RNA crcZ, which sequesters Crc away from its mRNA targets. The CbrAB two-component system transcriptionally regulates levels of crcZ (Figure 2B; Sonnleitner et al., 2009) in response to signals that have yet to be described.

Consistent with the absence of LasR phenotypes in evolved ∆cbrA or ∆cbrB cultures, Pool-Seq analysis found no mutations in lasR on either Day 4 or 6 (Figure 2C, pink and Supplementary file 1) which was in striking contrast to the multiple LasR alleles observed in wild type cultures. The absence of lasR mutations in the ∆cbrA and ∆cbrB derivatives was not due to differences in mutation frequency or number of generations as other mutations in distinct pathways under selection (e.g. fleR in Figure 2C) were present at comparable levels in all cultures (Supplementary file 1 for data). In addition, strain PA14 wild type and the ∆cbrA mutant had similar growth patterns as assessed by daily optical density measurements (Figure 2—figure supplement 2C). We also assessed a number of factors other than differential growth that could affect the rise of LasR lineages. A previous report Heurlier et al., 2005 found that LasR strains in the PAO1 background undergo less severe alkaline-induced lysis in another complex medium (nutrient yeast broth) when grown aerobically, but we found no evidence of differential lysis in LB between wild-type and ∆lasR strains under our conditions (Figure 1—figure supplement 1A). Furthermore, buffering the medium to pH 7 suppressed medium alkalinization (from pH of 6.8–8.5) and lysis (Crocker et al., 2019), but not the rise of LasR lineages; though, the kinetics of LasR lineage detection was delayed with buffering (Figure 2—figure supplement 2D and Sandoz et al., 2007). Lastly, to assess potential differences in toxicity of the wild type and ∆cbrB mutant culture supernatants toward LasR cells through the production of secreted factors (Yan et al., 2018), we grew the ∆lasR mutant in spent filtrate from wild-type and ∆cbrB cultures; no significant differences in colony forming units were observed (Figure 2—figure supplement 2E).

The activation of CbrAB increases growth on diverse metabolites by inducing crcZ which sequesters Crc away from the targets that it translationally represses (Figure 2B for pathway). In D’Argenio et al. (D’Argenio et al., 2007), higher CbrB levels were observed in LasR strains in a proteomics analysis, but no direct interactions between LasR and components of CbrA-CbrB-crcZ-Crc pathway have been described. Because CbrA, CbrB, and crcZ act to repress Crc, we hypothesized that if the loss of LasR function led to higher activity of the CbrA-CbrB-crcZ pathway and less Crc translational repression, we might also observe loss-of-function mutations in the genes encoding Crc or Hfq in the absence of cbrB (Figure 2B). Interestingly, the pooled genome sequence data from the Day 4 (open symbols) and Day 6 (grey symbols) populations evolved in the ∆cbrA and ∆cbrB backgrounds identified seven different mutations in crc, including three nonsense mutations, four missense mutations, and six indels, and these were among the most abundant mutations in the ∆cbrB mutant cultures; no crc mutations were identified in the PA14 wild type evolved populations (Figure 2C). In ∆cbrB, crc mutant alleles showed the largest rise between Day 4 and Day 6 across all three replicate cultures (Supplementary file 1). In the ∆cbrA passaged cultures, we also identified a rise in hfq mutations within the coding and upstream intergenic regions (Figure 2C and Supplementary file 1 for sequence data) in addition to mutations in crc. The changes in relative abundances of alleles with mutations in crc and either the promoter or coding regions of hfq across the 2 days suggested that hfq mutations and crc mutations were in different backgrounds (Supplementary file 1).

To assess Crc-Hfq function in evolved strains, we leveraged Crc translational repression of the amidase AmiE, which cleaves the prototoxin FAA to the toxic FA (Figure 2D for pathway) (O’Toole et al., 2000). Succinate, which downregulates CbrAB activity, maintains repression of AmiE, thereby enabling wild type to grow in the presence of FAA. In the absence of functional Crc or its co-repressor Hfq, cells synthesize AmiE, and FAA conversion into FA inhibits growth. As expected, on medium with succinate, FAA inhibited growth of the ∆crc mutant, but did not affect growth of the complemented ∆crc +crc strain, the wild type, and the ∆cbrA and ∆cbrB mutants. However, in passaged ∆cbrA and ∆cbrB cultures, spontaneous mutants in the population gave rise to larger colonies (Figure 2C, top), and these isolates were FAA sensitive (Figure 2D) supporting the model that in the ∆cbrA and ∆cbrB backgrounds, mutations that abolished Crc or Hfq activity arose. Secondary mutants with FAA sensitivity also arose in the DH2417 ∆cbrB background upon passaging, indicating that this phenomenon was not unique to the PA14 background, and another study also reported crc and hfq mutants in the absence of cbrB (Boyle et al., 2017). Given the apparent selection for decreased Crc function in ∆cbrA and ∆cbrB, and the requirement of cbrA or cbrB for LasR strain selection, we hypothesized that increased CbrAB activity may be a trait that increases the fitness of LasR strains.

To complement the genetics approach of evolution assays in cbrAB mutants, we monitored the rise of LasR lineages in LB medium supplemented with succinate, which inhibits CbrAB activity (Sonnleitner et al., 2009). Medium amendment with 40 mM (pH 7) succinate was sufficient to repress CbrB-regulated crcZ small RNA expression in ∆lasR to levels reminiscent of ∆lasR∆cbrB (Figure 2D). lasR mutants still responded to succinate; succinate reduced crcZ levels in ∆lasR and enabled ∆lasR growth on medium with FAA due to Crc activity (Figure 2E, inset). This indicated that ∆lasR retains the Crc-Hfq mediated translational repression when succinate is present. Succinate amendment suppressed the rise of LasR phenotypes in PA14 wild type (Figure 2F).

Elevated cbrB and crcZ expression and reduced Crc-dependent repression are sufficient to recapitulate the growth advantages of LasR strains

CbrAB activity induces the expression of crcZ, which sequesters Crc. We found that the ∆lasR mutant had ~two fold higher crcZ levels compared to wild type, suggesting higher activity of the CbrAB two- component system in LasR strains (Figure 3A). Previous work reported higher yields on phenylalanine for LasR relative to LasR+ strains concomitant with elevated CbrB protein levels in a proteomics analysis (D’Argenio et al., 2007). Thus, we first used phenylalanine as a growth substrate to further dissect the activity of the CbrAB-crcZ-Crc pathway (Figure 2B for pathway) in LasR strains. In planktonic cultures in medium with phenylalanine as a sole carbon source, the ∆lasR strain obtained significantly reduced lag (Figure 3B) and higher yields (Figure 3C) than the wild type, and the enhanced growth phenotype was complementable by lasR. As previously reported, growth on phenylalanine depended on cbrB; the ∆cbrB and ∆lasRcbrB mutants grew similarly poorly and their growth yield could be fully complemented by expressing cbrB (Figure 3B and C). Deletion of crc in the ∆lasR∆cbrB strain also restored growth to levels comparable to the ∆lasR and ∆lasR∆cbrB+cbrB strains (Figure 3B and C) indicating Crc repression of phenylalanine catabolism in the cbrB mutant. Overexpression of either cbrB or its target crcZ, which acts as a Crc-sequestering agent, was sufficient to improve yields on phenylalanine relative to the empty vector control (Figure 3D).

Figure 3 with 1 supplement see all
Increased CbrB activity of LasR strains is necessary and sufficient to promote growth on non-repressive substrates like phenylalanine via Crc.

(A) CbrB promotes the transcription of crcZ, and crcZ thus can be a readout of CbrB transcriptional activity. crcZ expression was measured by qRT-PCR relative to the average expression of the housekeeping genes rpoD and rpsL in cultures of PA14 WT and ∆lasR strains grown to OD600 nm = 1 from four independent experiments. *, p = 0.0334 as determined by Student’s paired two-tailed t-test. (B) Early growth (2 hr) and (C) Final yield (24 hr) on phenylalanine (Phe) as a sole carbon source shows enhanced growth for ∆lasR, cbrB dependence, and the requirement for cbrB is abolished by deletion of crc. Each point is the average of three replicates, repeated three independent days. Statistical significance determined by one-way ANOVA with Šídák’s multiple comparisons test. ns, not significant. *, p < 0.05. **, p < 0.005. ****, p < 0.0001. (D) Final yield on Phe under (0.2%) arabinose-inducing conditions for the PA14 WT strain expressing an empty vector or crcZ, and cbrB overexpression constructs. Each point is the average of three replicates, performed on three separate days. Statistical significance determined by one-way ANOVA with multiple hypothesis correction as above.

The CbrB- and Crc-controlled growth advantage on phenylalanine for LasR strains in planktonic cultures was also apparent in colony biofilms (Figure 3—figure supplement 1A). In colony biofilms, again, ∆lasR had improved growth on phenylalanine, that was dependent on cbrB and the growth defect of the lasRcbrB mutant could be rescued by deletion of crc (Figure 3—figure supplement 1A). The same pattern was observed on other substrates for which catabolism is under the control CbrAB-Crc pathway such as glucose and mannitol (Figure 3—figure supplement 1A). While deletion of crc was able to restore enhanced growth to the ∆lasRcbrB mutant, ∆crc did not grow as robustly as the ∆lasR mutant which is consistent with the detection of LasR lineages but not Crc lineages in passaged wild type cultures. Thus, LasR strains from stationary phase cultures appear to be primed for growth on multiple single carbon sources under CbrB-Crc control and reach higher final yields on these substrates.

LasR strains have CbrB-dependent growth advantages on metabolites enriched in progressive cystic fibrosis lung infections

Loss-of-function mutations in lasR are commonly detected in samples from chronic P. aeruginosa lung infections in pwCF, and these mutants have been correlated with a more rapid rate in lung function decline (Hoffman et al., 2009). To determine the metabolite milieu in the CF lung, we performed a metabolomics analysis of bronchioalveolar lavage samples collected from 10 pwCF and 10 non-CF individuals (Supplementary file 3). The pwCF were infected with diverse pathogens and had varying lung function, which was measured as forced expiratory volume in 1 s and presented as the percent expected at one’s age (%FEV1). Over 300 compounds were measured, and no uniquely microbial metabolites were noted. Many compounds were higher in the CF population, but some were unchanged (e.g glucose) and others were higher in non-CF samples (e.g adenosine and glutathione as previously published Esther et al., 2008; Fitzpatrick et al., 2014; Supplementary file 4).

In a principal component analysis (PCA), samples from non-CF individuals clustered together while those from pwCF were more spread. Samples from pwCF with high lung function (112 or 113 %FEV1) grouped among the non-CF samples (Figure 4A). The metabolites that contributed strongly to the first principal component, PC1, showed a significant inverse correlation with %FEV1 including phenylalanine, arginine, lactate, and citrate (Figure 4B). As with phenylalanine (Figure 3B and C & Figure 3—figure supplement 1A), the ∆lasR strain had growth advantages on arginine, lactate, and citrate that were controlled by CbrB and Crc (Figure 3—figure supplement 1A, B).

Figure 4 with 1 supplement see all
CbrB-dependent growth advantages may contribute to lasR mutant selection in distinct nutrient profiles of progressive cystic fibrosis airways.

(A) The first two dimensions (PC1 and PC2) of a principal component analysis of log normalized metabolite counts from bronchoalveolar lavage (BAL) samples collected from cystic fibrosis (CF, blue filled) and non-cystic fibrosis (non-CF, gray open) donors explain 62.84% and 15.08% of the variation in the data, respectively. PC1 separates the metabolite data by relative lung function as measured by percent forced expiratory volume in 1 s (%FEV1) for samples from people with CF. The %FEV1 is overlayed for CF-donor samples with text. Samples from non-CF donors group more closely with CF-donor samples that have high lung function. (B) Spearman correlation analysis of the relative phenylalanine (orange), arginine (aqua), lactate (yellow), citrate (magenta), and adenosine (gray) metabolite counts in the BAL samples relative to %FEV1 with exact p-values of 0.010, 0.005, 0.002, 0.041, and 0.714, respectively. Best fit semilog lines shown for visual clarity. (C) Comparison of the final yield measured after 24 hr for strains PA14 wild type and ∆lasR across a subset of carbon sources in BIOLOG growth assays for which the metabolite was found to be in higher abundance in CF-donor relative to non-CF donor BAL samples. Bold font indicates carbon sources analyzed in Figure 3 and Figure 3—figure supplement 1. Number in parenthesis refers to the ratio of the average counts for each metabolite in CF relative to non-CF samples. **, p-value = 0.003 as determined by two-tailed paired t-test comparing growth across CF-enriched metabolites between the wild type and ∆lasR strains. Succinate (gray diamond, black dashed line) was not detected (nd) in the BAL samples and thus not included in the statistical analysis, but the growth data is shown for reference. (D) Observed percentage of colonies with LasR phenotypes over the course of evolution from strains (top) PA14 WT or (bottom) CF isolate (both green circles) with ∆cbrB (purple squares) derivatives in artificial sputum medium (ASM), which was designed to recapitulate the CF lung nutritional profile. ns, not significant (p-value > 0.9); ***, p = 0.0008; ****, p < 0.0001 as determined by ordinary two-way ANOVA with Šídák’s multiple comparisons test.

We identified the 20 carbon sources that were most enriched in CF samples including those that correlated inversely with lung function, then used a BIOLOG phenotype array to assess whether the trend of greater yield for the ∆lasR strain persisted across this set. We found a significantly higher yield for the ∆lasR strain when we analyzed growth of the WT and ∆lasR across this group of 20 carbon sources suggesting that ∆lasR has improved growth on many of the nutrients available in the lung (Figure 4C).

To further test the hypothesis that the growth phenotypes of LasR strains can promote selection in the nutrient environment of the CF lung, we performed evolution experiments using both strain PA14 and a LasR+ CF clinical isolate in a medium designed to more closely recapitulate the nutritional profile of the cystic fibrosis airway. Upon absolute quantitation, we observed good concordance between the relative abundances of amino acids found in BAL fluid and reported for sputum (Palmer et al., 2005) which served as a basis for an artificial sputum medium, ASM (Figure 4—figure supplement 1; Clay et al., 2020) that was based on a previously reported synthetic CF medium (SCFM2) (Palmer et al., 2005). LasR strains evolved in both strain backgrounds (Figure 4D) with kinetics similar to what was observed in LB medium (Figure 1B). Parallel evolution experiments in ASM initiated with ∆cbrB derivatives did not exhibit a rise in LasR phenotypes in either strain background to suggest that CbrAB activity was again a contributor to the fitness of lasR LOF mutants.

Discussion

Through mathematical modeling, experimental evolution, and competition assays, we found that the rise of problematic P. aeruginosa LasR variants frequently observed in disease could be explained by increases in yield and decreases in lag during growth on carbon sources abundant in the lung environment (Figure 5). In fact, the steady state growth rate for ∆lasR was slightly less than that for the wild type, which is consistent with the model that there are frequently tradeoffs between a shorter lag phase and overall growth rate (Basan et al., 2020). Interestingly, CF-adapted P. aeruginosa isolates have been found to have slower in vitro growth rates than other strains (Yang et al., 2008). Other factors will impact the relative fitness of LasR+ and LasR cells across different growth phases (Figure 5) including oxygen availability and pH buffering capacity, which may lead to differential lysis (Heurlier et al., 2005), or the need for (or exploitation of) proteases to gain access to growth substrates (Van Delden et al., 1998; Sandoz et al., 2007).

CbrAB activity contributes to the positive selection of LasR strains in complex media.

LasR strain fitness relative to wild type is shown across growth phases, including lag, exponential growth, stationary, and death phases. Relative fitness of the LasR strain (dotted black line) is calculated from the experimentally determined monoculture growth data of strains PA14 wild type (WT) and ∆lasR over time. Values above one indicate a LasR strain fitness advantage over the WT strain during that growth phase. Circled insets show representative cartoons of LasR- (beige) and LasR+ (green) cells at each growth phase to indicate dividing or lysing cells (burst cells) across growth stages. The heights of the peaks or valleys of the relative fitness lines can be altered by several modulating factors including those that contribute to the positive and negative selection of LasR strains. Other modulating factors reported or suggested in the literature include inter- and intra- species competition, extracellular protease, immunoclearance, and oxygenation which are likely condition dependent. In the absence of CbrA or CbrB (CbrAB-, dotted purple line) or in the presence of succinate (one CbrAB repressive substrate), the relative growth of LasR strains is lower resulting in a reduction in the observed selection. This could be partially relieved in the CbrAB- background through disruption of Crc or Hfq function (blue dotted line), restoring activity through the pathway.

The overlap between the model-predicted and observed percentages of LasR strains over the course of the evolution regime suggests that the described social advantage resulting from QS dysfunction for LasR strains (i.e. social cheating) is not necessary to explain the timing and kinetics of the initial rise of LasR strains under our conditions. However, social interactions that benefit LasR- strains may be evident where the model estimates percentages that fall below or on the lower range of that experimentally observed, such as Day 4 or 6. A more detailed discussion of when social interactions are required is found below.

The data presented support the model that that increased growth of LasR cells on many amino acids, sugars, and lactate is due to higher CbrAB-controlled crcZ levels which downregulates metabolism under Crc control, and these findings nicely parallel studies by D’Argenio et al. (D’Argenio et al., 2007) that found higher levels of CbrB in LasR isolates. In PA14 ∆cbrA and ∆cbrB mutants, lasR LOF mutations did not arise, but mutations in crc and upstream of hfq were observed. As crc mutations phenocopy some of the growth advantages of the lasR mutants (Figures 2C and 3, Figure 3—figure supplement 1), the importance of derepressed catabolism for fitness is underscored. It is interesting to note that there were differences in the relative dependence on CbrB for the selection for LasR between strains PA14 and DH2417, and in ASM the dependence on cbrB for the selection of LasR strains increased in both strains (Figure 4D) suggesting that different environments may alter the importance of different LasR- and CbrB-controlled targets important for fitness that have yet to be elucidated. Though deletion of cbrA or cbrB can have pleiotropic effects (Yeung et al., 2011), we did not observe differences in density, quorum sensing regulation, production of quorum sensing controlled factors such as proteases, lysis in stationary phase, or overall mutation accumulation between wild type, ∆cbrA, and ∆cbrB that could explain differences in the rise of LasR subpopulations. Furthermore, environmental modification of CbrB activity by the addition of succinate to LB (Sonnleitner et al., 2009) also suppressed the emergence of LasR strains in the wild type. Because CbrAB activity can still be suppressed by succinate in LasR cells (Figure 2E), LasR variants were not strictly ‘de-repressed’, and this is consistent with the fact that ∆lasR and ∆crc growth patterns were not identical. Unlike lasR mutations, crc mutations are not commonly observed in clinical isolates (Winstanley et al., 2016) and crc mutants have been shown to be under negative selection in Tn-Seq experiments (Lorenz et al., 2019).

Analysis of BAL fluid revealed higher levels of substrates such as lactate and amino acids, which require CbrB for consumption, in samples from pwCF, and these findings are consistent with other more targeted analyses of CF airway samples (Bensel et al., 2011; Twomey et al., 2013). Consistent with our finding that higher levels of certain metabolites correlated with worse CF lung disease, other studies including that of Esther et al., 2016 found a correlation between total metabolites and neutrophil counts suggesting host cell lysis, along with lysis of microbial cells, may be a major contributor to a shift in the metabolome. CF-lung derived P. aeruginosa isolates can have amino acid auxotrophies and enhanced amino acid uptake (La Rosa et al., 2019) which supports ready access to amino acids in vivo. Several CF isolates show reduced succinate assimilation to suggest the uptake of less preferred substrates over the course of adaptation, which may indicate decreased Crc activity over time (Jørgensen et al., 2015; La Rosa et al., 2018).

Our model predicts LasR strains benefit from growth advantages that might be present when new nutrients become available (analogous to lag phase) and in dense populations when improved yields for the ∆lasR mutant emerges; due to a slower steady state growth rate, we predict that LasR strains would not emerge under steady state growth conditions such as in a chemostat. Indeed, the advantages of decreased lag phase in cultures has been proposed to be a universal adaptation in dynamic environments (Basan et al., 2020; Bertrand and Margolin, 2019). Thus, the frequent emergence of LasR lineages in the CF lung and other disease settings suggests that P. aeruginosa often undergoes growth transitions in vivo, possibly due to fluctuating local conditions, spatial heterogeneity, or the result of complex competition between bacterial and host cell types. The CbrB-dependent rise of LasR strains in the complex CF mimetic medium (i.e. artificial sputum medium, ASM) alongside the positive selection observed in minimal media with CF relevant substrates (Scribner et al., 2022) shown to require CbrB for LasR strain growth enhancement suggests that the growth advantages of lasR mutants may be sufficient to overcome any potential negative selective pressures mediated by the host, neighboring microbes, or inaccessibility to nutrients like complex protein or adenosine. In addition, the loss of LasR function enables other inherent advantages that contribute to competitive fitness including resistance to lysis under conditions of high aeration, enhanced microoxic fitness, enhanced RhlR activity (Chen et al., 2019; Clay et al., 2020; Heurlier et al., 2005), and altered intraspecies interactions (Mould et al., 2020) which may be relevant in the complex and dynamic nutritional environment of the CF airway over the course of disease. The connection between these phenotypes and the CbrAB-crcZ-Crc pathway is not yet clear.

The increased growth in post-exponential phase cultures for LasR strains bears similarities to mutations that arise in other microbes. For example, the selection for rpoS mutants in stationary phase cultures of E. coli (Finkel and Kolter, 1999; Zambrano et al., 1993; Zinser and Kolter, 2000) is also dependent on nutrient accessibility (Farrell and Finkel, 2003) with enhanced amino acid catabolism as a major contributor to E. coli lineages with growth advantages in stationary phase (GASP) (Zinser and Kolter, 1999). While the rise of rpoS mutants in laboratory settings required pH-driven lysis (Farrell and Finkel, 2003), LasR strains still evolved in buffered medium suggesting distinct mechanisms for the metabolic advantages of lasR mutants. It is worth noting that none of the common GASP mutations (rpoS, lrp, or ybeJ-gltJKL) were identified in our in vitro evolution studies (Supplementary file 1). We considered that the enhanced growth of LasR strains in post-exponential growth phases may be due to differences in ppGpp signaling, given growth arrest as part of the stringent response modifies the expression of QS-regulated genes (van Delden et al., 2001). However, no mutations in relA or spoT, the two ppGpp synthases, were observed. The mechanism of increased CbrB activity in ∆lasR remains an unresolved question that is relevant to P. aeruginosa biology and may aid in the identification of the signals that activate the CbrA sensor kinase which influences clinically relevant phenotypes including virulence and antibiotic resistance (Yeung et al., 2011). Our working model is that the upregulation of CbrB transcription of crcZ increases levels of transporters and catabolic enzymes due to the release from Crc repression, and this enhanced substrate uptake alters intracellular metabolite pools driving metabolism in accordance with Le Chatelier’s principle (Monod, 1949). Thus, quorum sensing mutants can maintain higher growth rates at lower substrate concentrations than for quorum-sensing intact cells.

The repeated observation that LOF mutations readily arise in diverse settings provokes the question of how quorum sensing is maintained. Several elegant mechanisms that address this point have been described. First, the wiring of the LasR regulon is such that while there are growth advantages on many substrates present in the lung, there are growth disadvantages on other important nutrient sources (e.g. adenosine and proteins and peptides Heurlier et al., 2005). Social cheating can promote the rise of LOF mutants in protease-requiring environments (Diggle et al., 2007; Hassett et al., 1999). Second, there are quorum-sensing controlled ‘policing’ mechanisms through which LasR+ strains restrict the growth of LasR types through the release of products toxic to quorum-sensing mutants (Castañeda-Tamez et al., 2018; García-Contreras et al., 2020; Wang et al., 2015). Lastly, there are other tradeoffs such as sensitivity to oxidative stress that may limit LasR lineage success (Hassett et al., 1999). Quorum sensing exerts metabolic control in other diverse microbes beyond P. aeruginosa. Thus, these data provide insight into generalizable explanations for the benefits of metabolic control in dense populations and indicate drivers for frequent loss-of-function mutations in quorum-sensing genes such as agr in Staphylococcus aureus and hapR in Vibrio cholerae (Mould and Hogan, 2021).

Together, these data highlight the power of coupling in vitro evolution studies with forward and reverse genetic analyses. Other benefits to this approach include the ability to dissect subtle differences between pathway components. For example, multiple mutations in crc repeatedly rose in ∆cbrA-, but not in ∆cbrB-derived populations, and multiple mutations in hfq rose in ∆cbrB-, and not in ∆cbrA-derived populations. While CbrA and B work together as do Crc and Hfq, these observations may provide a foothold into key distinctions that could yield mechanistic insights. In the future, the ability for deep sequencing of infection populations and analysis of evolutionary trajectories may aid diagnoses and treatment decisions in beneficial ways.

Materials and methods

See Key Resources Table in supplement for additional details on key reagents.

Strain construction and maintenance

Request a detailed protocol

In-frame deletions and complementation constructs were made using a Saccharomyces cerevisiae recombination technique described previously (Shanks et al., 2006). The cbrB and crcZ expression vectors were constructed by HiFi Gibson assembly with the NEBuilder HiFi DNA Assembly kit according to manufacturer’s protocol. All plasmids were sequenced at the Molecular Biology Core at the Geisel School of Medicine at Dartmouth. In frame-deletion and complementation constructs were introduced into P. aeruginosa by conjugation via S17/lambda pir E. coli. Merodiploids were selected by drug resistance and double recombinants were obtained using sucrose counter-selection and genotype screening by PCR. Expression vectors were introduced into P. aeruginosa by electroporation and drug selection. All strains used in this study are listed in Supplementary file 6. Bacteria were maintained on lysogeny broth (LB) with 1.5% agar. Yeast strains for cloning were maintained on YPD (yeast extract-peptone-dextrose) with 2% agar. Artificial sputum medium (ASM) was made as described previously (Clay et al., 2020).

Mathematical model

Request a detailed protocol

Growth parameters were determined from 5 mL grown LB cultures inoculated as described in the experimental evolution protocol and the monocarbon growth below. In brief, a 16 h overnight LB culture was normalized to OD600 nm = 1 in LB, and a 250 µL aliquot of the normalized culture was used to inoculate 5 mL fresh LB for an approximate OD600 nm = 0.05 at time zero. The density (OD600 nm) was measured for up to 48 hr by taking a 10–100 µL aliquot at the designated time intervals from the 5 mL culture tube with dilution into LB as appropriate in a 96-well plate (100 µL total per well) for OD600 nm measurement using a Spectramax M2 microplate reader with Softmax Pro 6.5.1 software. Lag and growth rate were measured in separate experiments from those used to monitor lysis so that the volume in the 5 mL cultures tubes never dropped below 10% of the starting volume. See Supplementary file 7 for additional details for the parameter choices used in the mathematical model and Source code 1 for the Matlab script.

Experimental evolution

Request a detailed protocol

Experimental evolution was modeled after work by Heurlier et al., 2005. A single colony of each strain was used to inoculate a 5 mL LB culture in 13 mm borosilicate tubes. The tubes inoculated with a single colony were grown for 24 hr at 37 °C on a roller drum. The 24 hr grown culture was adjusted to OD600 nm = 1 in LB based on OD600 nm reading of a 1–10 dilution in LB of the 24 hr culture in a 1 cm cuvette using a Spectronic GENESYS 6 spectrophotometer. Separate 250 µL aliquots of the OD600 nm normalized cells was sub-cultured into three tubes containing 5 mL fresh media to initiate the evolution experiment (i.e. time 0) with three distinct replicate cultures per experiment. At time of passage every two days, 25 µL of culture was transferred into 5 mL fresh media. Every day (or as indicated) cultures were diluted and spread onto LB agar plates using sterile glass beads for phenotype distinction. The LB agar plates were incubated for ~ 24 hr at 37 °C and then left at room temperature for phenotype development. The sheen LasR colony morphologies were counted, and the percentage of LasR phenotypes calculated based on total CFUs. All experimental evolutions in LB were repeated on at least three independent days with three replicates of each strain per experiment unless otherwise stated. The ASM and succinate amended medium evolutions were completed on two separate days. In the case of ∆rhlR and ∆anr, the three replicates were inoculated from three independent overnights. Data visualization and statistical analysis was performed in GraphPad Prism 9 (version 9.2.0).

gDNA extraction, sequencing, SNP calling of Pool-Seq data

Request a detailed protocol

Between 100 and 150 random colonies were scraped and pooled from the LB agar plates that were counted and used to measure the percent of colonies with LasR phenotypes at Days 4 and 6 from a representative WT-, ∆crbA-, and ∆cbrB-initiated evolution experiment. For plates containing a total of 100–150 colonies, all colonies on the plate were collected for a single pooled genomic DNA extraction. If more than 150 colonies were on a plate, the plate was divided equally, and all colonies in an arbitrary section were collected to ensure genomic DNA was extracted from a similar number of colonies for each sample. Scraped up cells were pelleted briefly in a 1.5 mL Eppendorf tube via a short spin, resuspended in 1 mL PBS, vortexed briefly, and gDNA was subsequently extracted from a 50 µL aliquot of cell resuspension via the Master Pure Yeast DNA purification kit according to manufacturer’s protocol with RNAase treatment. A 2.5 µg aliquot was submitted for Illumina sequencing (1Gbp) at the Microbial Genome Sequencing (MiGs) Center on the NextSeq 2000 platform. The resulting forward and reverse reads were trimmed with bcl2fastq (v2.20.0422) to remove Illumina adaptor sequences during the demultiplexing process. Both forward and reverse read files were aligned and compared to the complete and annotated UCBPP-PA14 genome available on NCBI (accession GCF_000014625.1) using the variant caller BreSeq (Deatherage and Barrick, 2014) (version 0.35.4) with the -p option for polymorphisms and a 5% cutoff. Specifically, the following command was used: breseq -p -j 10 r [reference file] [sample name]_.fastq.gz [sample name]_fastq.gz -o [output file name]. This provided an output file that specified variations from the reference genome and listed their respective fractions of the total reads. These fractions were treated as estimations of genotype proportions in the population. Variants at fixation (100%) across all 18 samples (three strains, 2 days) were excluded from follow-up analysis as potential differences in strain background that differed from the reference genome at the start of the experiment. All sequencing data is available on the Sequence Read Archive with the accession number PRJNA786588.

Milk proteolysis

Request a detailed protocol

Brain Heart Infusion Agar was supplemented with powdered skim milk dissolved in water to a final concentration of 1%. The evolved isolates selected on basis of ‘sheen’ colony morphology were grown in a 96-well plate with 200 µL LB per well for 16 hr. Milk plates were inoculated with ~ 5 µL of culture using a sterilized metal multiprong inoculation device (Dan-Kar) and incubated at 37 °C for 16 hr. PA14 WT and ∆lasR strains were included as controls. Colonies which showed a halo of clearing larger than the ∆lasR control strain were considered protease positive.

Acyl homoserine lactone autoinducer bioreporter assays

Request a detailed protocol

Protocol as described in Mould et al., 2020. Briefly, 100 µL of OD600 nm normalized LB overnight cultures (OD600 nm = 0.01) of the AHL-synthesis deficient reporter strains DH161 (3OC12HSL-specific) or DH162 (3OC12HSL or C4HSL responsive) with AHL-responsive promoters to lacZ (Whiteley and Greenberg, 2001; Whiteley et al., 1999) were bead spread on LB plates containing 150 µg/mL 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (XGAL, dissolved in DMSO). Inoculated plates were allowed to dry 10 min in a sterile hood. Once dry, 5 µL of either the test strains or control cultures (PA14 wild type and ∆lasR strains) were spotted onto the inoculated reporter lawns. After the spots dried, plates were incubated at 37 °C for 16 hr then stored at 4 °C to allow for further color development, if necessary, based on wild-type colony activity. The blue halo that formed around the colony was interpreted as AHL activity. The levels of AHL produced are approximated by the size of the blue halo formed around the colony.

Competition assays

Request a detailed protocol

Competition assays were performed by competing strains against an att::lacZ strain as previously reported (Clay et al., 2020). Overnight cultures of att::lacZ competitor and test strains were normalized to OD600 nm = 1 and mixed in the designated ratios with either a wild type control or ∆lasR strain. Aliquots of 10–6 dilutions of the initial mixed inoculums were immediately plated on LB plates containing 150 µg/mL XGAL by spreading an aliquot of 25–50 µL with sterilized glass beads. Roughly 100–200 colonies were counted to determine the initial ratios of PA14 att:lacZ to ∆lasR or the WT control strains by blue:white colony phenotype, respectively. To begin the competition experiment, a 250 µL aliquot of each undiluted mixed inoculum was sub-cultured into 5 mL fresh LB medium and incubated on a roller drum at 37 °C for 6 hr. After 6 hr, the cultures were collected, diluted by 10–6 in fresh liquid LB, and plated as previously stated for blue:white colony screening. The LB plates containing XGAL were incubated overnight at 37 °C prior to counting. Competitions were repeated on three separate days.

Kinase mutant evolution screen

Request a detailed protocol

Using an ethanol/flame sterilized metal multiprong inoculation device (Dan-Kar), the kinase mutant library (Wang et al., 2021) was inoculated into a 96-well plate with 200 µL LB per well for 24 hr shaking at 37 °C. The 24 hr grown cultures were used to inoculate two 96-well plates with each kinase mutant (including PA14 WT control) in triplicate. These cultures were grown for 48 hr upon which 2 µL was transferred to new 96 well plates with fresh 200 µL LB liquid per well. Every 2 days, the wells containing the wild-type replicates were diluted by 10–6 in fresh LB and 25 µL was bead spread onto LB for phenotypic distinction based on sheen colony morphology. At Day 14, when all wildtype replicates contained at least 50% LasR phenotypes, all wells were diluted and plated as stated previously for determination of sheen colony morphology. A secondary screen in 5 mL LB (as described above in Experimental Evolution section) was initiated with those mutant strains which did not show any LasR phenotypes across all three replicates in the microtiter assay at Day 14. The Circos plot summarizing the screen data was generated using BioCircos (Cui et al., 2016) in R (version 4.0.2) and re-colored in Adobe Illustrator.

Filtrate toxicity

Request a detailed protocol

Based on a protocol used previously (Abisado et al., 2021), strains were grown 16 hr in LB (5 mL) on a roller drum at 37 °C, centrifuged at 13 K RPM for 10 min in 2 mL aliquots, and the resulting supernatant was filter sterilized through a 0.22 µm pore filter. Per 5 mL filtrate, 250 µL of fresh LB was added. A 16 hr, grown LB culture (5 mL) of PA14 ∆lasR was normalized to an OD600 nm = 1 in LB, and 250 µL was used to inoculate 5 mL of the filtrate-LB mixture. The ∆lasR cultures were grown for 24 hr at 37 °C on the roller drum upon which colony counts were determined by bead spreading an appropriate dilution on LB plates. Data visualization and statistical analysis were performed in GraphPad Prism 9 (version 9.2.0).

Fluoroacetamide sensitivity assay

Request a detailed protocol

Strains were inoculated (either by patching from plates or by spotting 5 µL of 16 h LB grown culture) onto plates containing 1.5% agar with M63 salts,10 mM lactamide, and 40 mM succinate with or without 2.5 mg/mL filter-sterilized fluoroacetamide (FAA) dissolved in water based on protocol by Collier et al., 2001. Relative growth was compared in the presence and absence of FAA. PA14 wild type and ∆crc were included as controls in every experiment wherein wild type displays robust growth on FAA in the presence of succinate and the ∆crc strain, little to none.

Quantitative RT-PCR

Request a detailed protocol

The indicated strains were grown from single colonies in 5 mL LB cultures on a roller drum for 16 hr, normalized to an OD600 nm of 1, and 250 µL of normalized culture was inoculated into 5 mL fresh LB for a starting inoculum around OD600 nm = 0.05. The cultures were then grown at 37 °C on a roller drum until OD600 nm = 1 at which point a 1 mL aliquot of culture was pelleted by centrifugation for 10 min at 13 K RPM. Supernatant was removed, and the cell pellets were flash frozen in an ethanol dry ice bath. This was repeated on three separate days with one WT and one ∆lasR culture pair (n = 4) collected on each day or one ∆lasR and one ∆lasR∆cbrB culture pair (n = 3) each day. Pellets were stored at –80 °C until all sets of pellets were collected. RNA was extracted using the QIAGEN RNAeasy kit according to the manufacturer’s protocol, and 7 μg RNA was twice DNAse treated with the Turbo DNA-free kit (Invitrogen). DNA contamination was checked by semi-quantitative PCR with gDNA standard for 35 cycles with rpoD qRT primers; if DNA contamination was greater than 0.004 ng / μL, the sample was DNAse treated again. cDNA was synthesized from 400  ng of DNase-treated RNA using the RevertAid H Minus first-strand cDNA synthesis kit (Thermo Scientific), according to the manufacturer’s instructions for random hexamer primer (IDT) and a GC-rich template alongside an NRT control. Quantitative RT-PCR was performed on a CFX96 real-time system (Bio-Rad), using SsoFast Evergreen supermix (Bio-Rad) according to the following program: 95 °C for 30 s and 40 cycles of 95 °C for 5 s and 60 °C for 5 s followed by a melt curve with 65 °C for 3 s up to 95 °C in increments of 0.5 °C. Transcripts were normalized to the average rpoD and rpsL expression unless stated otherwise. rpsL and crcZ primers as designed in Xia et al., 2020. rpoD primers as designed in Harty et al., 2019. Data visualization and statistical analysis performed in GraphPad Prism 9 (version 9.2.0).

Mono-carbon growth

Request a detailed protocol

Single carbon sources were supplemented into M63 base (Neidhardt et al., 1974) and filter sterilized. A 16 hr overnight LB culture grown at 37 °C on a roller drum was normalized to an OD600 nm = 1 in 2 mL LB. For liquid growth curves, a 250 µL aliquot of the density adjusted culture was spiked into 5 mL fresh M63 medium with designated carbon source in triplicate, and growth was monitored using a Spectronic 20D+ (Spec20) hourly in 13 mm borosilicate tubes. Every point on the growth plots is the average of three replicates per day, repeated 3 days total. For colony biofilm growth, 5 µL of OD600 nm = 1 normalized culture was inoculated onto 1.5% agar plate of M63 medium containing the designated carbon source in singlicate and grown for 16 hr at 37 °C. Colonies were cored using the back of a P1000 tip and disrupted by 5 min on Genie Disrupter in 1 mL LB. Disrupted colony biofilms were serially diluted. 5 µL of the serial dilutions were plated and a 50 µL aliquot of diluted colony resuspension (10–6 or 10–7-fold, depending on condition/strain) was bead spread and counted for colony forming units. Colony biofilm growth was assessed on >5 independent days. Data visualization and statistical analysis performed in GraphPad Prism 9 (version 9.2.0).

Metabolomics of bronchioloalveolar lavage fluid and artificial sputum medium

Request a detailed protocol

Human samples from people with and without cystic fibrosis were obtained with informed consent following institutional review board-approved protocols at Geisel School of Medicine at Dartmouth. The investigators were blinded to the conditions of the experiments during data collection and analysis. To obtain relative metabolite counts, bronchioloalveolar lavage (BAL) fluid samples were briefly centrifuged to exclude large debri then the supernatant was flash frozen in liquid nitrogen. Samples were processed by Metabolon via LC/MS for relative metabolite amounts. Raw values from Metabolon were normalized to protein concentrations by the BioRad Bradford protein concentration or raw area counts per day sample run and then the values were rescaled to set the median to one. Missing values were imputed with the minimum rescaled value for that biochemical. Quantitative amino acid concentrations were determined for aliquots of the same BAL samples (lyophilized) using the Biocrates AbsoluteIDQ p180 kit at the Duke Proteomics Core Facility. The lyophilized samples of BAL were homogenized in water and 50/50 water/methanol respectively to extract metabolites. 25 µL of the BAL extract were utilized for preparation of the samples on a Biocrates AbsoluteIDQ p180 plate. A Waters Xevo-TQ-S mass spectrometer was utilized to acquire targeted metabolite quantification on all samples and quality control specimens. Raw data (in µM) was exported independently for the FIA-MS/MS and UHPLC-MS/MS acquisition approaches used in this kit. The BAL sample data were corrected for the dilution factor since 25 µL was used versus 10 µL of the standards that were used to calculate the quantitative calibration curve. Principal component analysis of log normalized counts or concentrations were performed in R (version 4.0.2) (R Development Core Team, 2021) using the prcomp() function and visualized with ggplot2 (Wickham, 2016) using ggfortify (Tang et al., 2016). Supplementary file 3 of sample metadata was compiled with sjPlot (Lüdecke, 2021) in R.

BIOLOG phenotyping assay

Request a detailed protocol

Two mL of LB overnight cultures grown at 37 °C on a roller drum were washed twice with M63 salts with no carbon source by repeated centrifugation (10 min, 13 K RPM) and resuspension into fresh medium. The washed cultures were normalized to an OD600 nm = 0.05 in 25 mL of fresh M63 salts base and 100 µL was used to resuspend dehydrated carbon sources on the bottom of PM1 and PM2 BIOLOG phenotype plates by repeated pipetting. Cells and resuspended carbon were transferred to a sterile flat bottom, black-walled 96 well plate and incubated at 37 °C, static. Every hour OD600 nm was monitored in a plate reader for 24 hr. Endpoint (24 hr) data is reported. Data visualization and statistical analysis performed in GraphPad Prism 9 (version 9.2.0).

Appendix 1

Appendix 1—key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Gene (Pseudomonas aeruginosa)PA14NCBIAccession: GCF_000014625.1Reference file
Strain, strain background (Saccharomyces cerevisiae)Saccharomyces cerevisiaePMID:16820502Cloning yeast
Strain, strain background (Escherichia coli)DH5aInvitrogenElectrocompetent cells
Strain, strain background (Escherichia coli)S17 λpirPMID:8226632Electrocompetent cells made in lab
Strain, strain background (P. aeruginosa)PA14 WTPMID:7604262Hogan Laboratory reference strain
Strain, strain background (P. aeruginosa)DH2417; NC-AMT0101-1-2PMID:16687478Chronic CF lung infection isolate with functional LasR allele
Strain, strain background (P. aeruginosa)PA14 WTPMID:33771779Laub Lab; strain background of kinase clean deletion mutants
Genetic reagent (P. aeruginosa)PA14 ∆lasRPMID:15554963
Genetic reagent (P. aeruginosa)PAO-MW1qsc102PMID:10570171; PMID:11544214AHL-sensing bioreporter; PAO1 lasIrhlI mutant with Tn5-B22, which contains promoterless lacZ located within PA1896 (hypothetical protein) at chromosomal location of 2,067,716. Responsive to 3OC12-HSL but not C4-HSL.
Genetic reagent (P. aeruginosa)PAO-MW1qsc131PMID:10570171; PMID:11544214AHL-sensing bioreporter; PAO1 lasIrhlI mutant with Tn5-B22, which contains promoterless lacZ, under phzC promoter control. Responsive to either 3OC12-HSL or C4-HSL but requires both for full activation.
Genetic reagent (P. aeruginosa)PA14 WT att::lacZPMID:31980538PA14 WT with constitutive expression of lacZ for competition assays
Genetic reagent (P. aeruginosa)PA14 ∆cheAPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆chpAPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆creCPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆uhpBPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆bfiSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆bphPPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_10770PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_11630PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆rocS1PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆narXPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆wspEPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_19340PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆mxtRPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆cpxSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆gtrSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_24340PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆rocS2PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_26810PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆sagSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆copSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆pfeSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆bqsSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_30700PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_30840PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆czcSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_32570PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_36420PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆ercSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆exaDPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆ercS’PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆parSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆kdpDPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_43670PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_45590PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_45870PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_46370PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_46980PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_48160PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆phoQPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_49420PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆fleSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆pirSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆gacSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆tctEPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆pprAPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆colSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_57170PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆roxSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆rcsCPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆pvrSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆pilSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆cbrAPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆pmrBPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆retSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_64580PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆aruSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆ntrBPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_68230PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆amgSPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆algZPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆phoRPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆kinBPMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆PA14_72740PMID:33771779
Genetic reagent (P. aeruginosa)PA14 ∆rhlRPMID:30936375
Genetic reagent (P. aeruginosa)PA14 ∆anrPMID:31527114
Genetic reagent (P. aeruginosa)PA14 ∆cbrBThis paperPA14 WT with in-frame deletion of cbrB (PA14_62540)
Genetic reagent (P. aeruginosa)PA14 cbrB::TnMPMID:22911607; PMID:16477005cbrB MAR2xT7 transposon insertion mutant
Genetic reagent (P. aeruginosa)DH2417∆cbrB; NC-AMT0101-1-2∆cbrBThis paperCF clinical isolate NC-AMT0101-1-2 (DH2417) with in-frame deletion of cbrB (PA14_62540)
Genetic reagent (P. aeruginosa)PA14 ∆crcThis paperPA14 WT with in-frame deletion of crc (PA14_70390)
Genetic reagent (P. aeruginosa)PA14 ∆crc + crcThis paperPA14 ∆crc with complementation of crc (PA14_70390) at the native locus
Genetic reagent (P. aeruginosa)PA14 ∆lasR + lasRPMID:31980538
Genetic reagent (P. aeruginosa)PA14 ∆cbrB + pMQ70 cbrB (plasmid)This paperPA14 ∆cbrB expressing arabinose inducible pMQ70 cbrB expression vector
Genetic reagent (P. aeruginosa)PA14 ∆lasRcbrBThis paperPA14 ∆lasR with in-frame deletion of cbrB (PA14_62540)
Genetic reagent (P. aeruginosa)PA14 ∆lasRcbrB + cbrBThis paperPA14 ∆lasRcbrB with complementation of cbrB (PA14_62540) at the native locus
Genetic reagent (P. aeruginosa)PA14 ∆lasRcbrB∆crcThis paperPA14 ∆lasRcbrB with in-frame deletion of crc (PA14_70390)
Genetic reagent (P. aeruginosa)PA14 ∆lasR∆crcThis paperPA14 ∆lasR with in-frame deletion of crc (PA14_70390)
Genetic reagent (P. aeruginosa)PA14 ∆lasR∆crc + crcThis paperPA14 ∆lasRcrc with complementation of crc (PA14_70390) at the native locus
Genetic reagent (P. aeruginosa)PA14 + pMQ72 EVThis paperPA14 WT expressing pMQ72 empty vector
Genetic reagent (P. aeruginosa)PA14 + pMQ70 cbrBThis paperPA14 WT expressing arabinose inducible pMQ70 cbrB expression vector
Genetic reagent (P. aeruginosa)PA14 + pMQ72 crcZThis paperPA14 WT expressing arabinose inducible pMQ72 crcZ expression vector
Recombinant DNA reagentpMQ30 EVPMID:16820502
Recombinant DNA reagentpMQ72 EVPMID:16820502
Recombinant DNA reagentpMQ70 EVPMID:16820502
Recombinant DNA reagentpMQ30_cbrB_KOThis paperpMQ30 plasmid for knocking out cbrb
Recombinant DNA reagentpMQ30_crc_KOThis paperpMQ30 plasmid for knocking out crc
Recombinant DNA reagentpMQ30_cbrB_KONThis paperpMQ30 plasmid for complementing cbrb at the native locus
Recombinant DNA reagentpMQ30_crc_KONThis paperpMQ30 plasmid for complementing cbrb at the native locus
Recombinant DNA reagentpMQ72_crcZThis paperpMQ72 plasmid backbone with arabinose inducible crcZ expression
Recombinant DNA reagentpMQ70_cbrBThis paperpMQ70 plasmid backbone with arabinose inducible cbrB expression
Sequence-based reagentpMQ72 crcZ OE 1 FThis paperPCR Primers; construct designgtttctccatacccgtttttttgggctagcGCACAACAACAATAACAAGCAACGACGAAG
Sequence-based reagentpMQ72 crcZ OE 2 RThis paperPCR Primers; construct designctagaggatccccgggtaccgagctcgaattcgaaatggtgtaaggcgaaggaaaaacgg
Sequence-based reagentpMQ70 cbrB OE 1 FThis paperPCR Primers; construct designctctctactgtttctccatacccgtttttttgggctagcgAGACGAGCgaattcACGTCGAGAGAGCtgaatacatggcac
Sequence-based reagentpMQ70 cbrB OE 2 RThis paperPCR Primers; construct designttgcatgcctgcaggtcgactctagaggatccccgggtacGTAACAGGTTGCAGGGTaccGTtacgagtcggccgaggcccc
Sequence-based reagentpMQ30 cbrB KO 1 FThis paperPCR Primers; construct designtaacaatttcacacaggaaacagctatgaccatgattacgaattcAGGAAGTGCTGATGTGGAACC
Sequence-based reagentpMQ30 cbrB KO 2 RThis paperPCR Primers; construct designGTAACAGGTTGCAGGGTGTTTATTCAGCTCTCTCGACGTGCT
Sequence-based reagentpMQ30 cbrB KO 3 FThis paperPCR Primers; construct designCACGTCGAGAGAGCTGAATAAACACCCTGCAACCTGTTACC
Sequence-based reagentpMQ30 cbrB KO 4 RThis paperPCR Primers; construct designaggtcgactctagaggatccccgggtaccgagctcgaattcCAGGGAGTGCTGGTTGTTACCGATGACTtc
Sequence-based reagentpMQ30 crc KO 1 FThis paperPCR Primers; construct designtaacaatttcacacaggaaacagctatgaccatgattacgaattcTGGAATACAGGCGCAGCAac
Sequence-based reagentpMQ30 crc KO 2 RThis paperPCR Primers; construct designTAGAAAAGCCGGCGCATGCGCTGGCTTTTTCGTGTCTGACGGGGCAAATGGCCCCCAAAATCACGTGCG
Sequence-based reagentpMQ30 crc KO 4 RThis paperPCR Primers; construct designctgcaggtcgactctagaggatccccgggtaccgagctcgaattcttggctgaccgccgagtacggcatgc
Sequence-based reagentpMQ30 crc KO 3 FThis paperPCR Primers; construct designTTTGAGCTCGGGTATCATACACGCACGTGATTTTGGGGGCCATTTGCCCCGTCAGACACGAAAAAGCCAG
Sequence-based reagentcbrB check FThis paperPCR primer, KO checkGCGTCTGCTCCCTGGCCAAG
Sequence-based reagentcbrB check RThis paperPCR primer, KO checkGTGGCGCTGGTGGCGACATC
Sequence-based reagentcrc check FThis paperPCR primer, KO checkGCTCGATGGCGAAACGAATG
Sequence-based reagentcrc check RThis paperPCR primer, KO checkGCGCTGGTGTTGACCATCATC
Sequence-based reagentcrcZ RT 1 FPMID:31911486PCR PrimersGCACAACAACAATAACAAGCAACG
Sequence-based reagentcrcZ RT 2 RPMID:31911486PCR PrimersAGTTTTATTCTTCTTCCGACTGGCT
Sequence-based reagentrpsL RT1FPMID:31911486PCR PrimersGTAAGGTATGCCGTGTACG
Sequence-based reagentrpsL RT 2 RPMID:31911486PCR PrimersCACTACGCTGTGCTCTTG
Sequence-based reagentrpoD RT 1 FPMID:30936375PCR PrimersCGCCGAGATCAAGGAAATCA
Sequence-based reagentrpoD RT 2 RPMID:30936375PCR PrimersTACTTCTTGGCGATGGAAATCA
Commercial assay, kitNEBuilder HiFi DNA AssemblyBiolabsCat. #: E2621LGibson cloning
Commercial assay, kitMaster Pure Yeast DNA purification kitLucigenCat. No.: MPY80200
Commercial assay, kitRNAeasy Mini kitQIAGENCat. No.: 74,104
Commercial assay, kitTurbo DNA-free kitThermo Fisher ScientificAM1907
Commercial assay, kitRevertAid H Minus First Strand cDNA synthesisThermo ScientificCat. No.: EP0451cDNA synthesis with IDT random hexamer
Commercial assay, kitSsoFast EvaGreen SupermixBIO-RADCat.#: 1725201
Commercial assay, kitZymoprep Yeast Plasmid Miniprep IIZymo ResearchCat. No.: D2004Yeast cloning
Commercial assay, kitBiocrates AbsoluteIDQ p180 kitbiocratesAmino acid. quantification
Chemical compound, drugBrain Heart InfusionBDSKU:211,059BBL Brain Heart Infusion
Chemical compound, drugAgarBDSKU:214,510Difco Agar, granulated (2 Kg pail)
Chemical compound, drugXGAL; 5-bromo-4-chloro-3-indolyl-β-D-galactopyranosideResearch Products InternationalB71800-5.0Stock dissolved in DMSO
Chemical compound, drugFluoroacetamideAldrich128341–5 Gdissolved in water, filter sterilized
Chemical compound, drugLactamideTokyo Chemical IndustryProduct Number: L0001
Chemical compound, drugMannitolSigmaM8429-500GD-Mannitol
Chemical compound, drugSuccinateSigmaS9512-500GSuccinic acid, to pH7 with NaOH
Chemical compound, drugPhenylalanineSigma-AldrichP2126-100GL-Phenylalanine
Chemical compound, drugArginineSigmaA5131-100GL-arginine monohydrochloride
Chemical compound, drugLactateFisher ScientificS326-500Sodium lactate syrup, 60% w/w
Chemical compound, drugGlucoseVWR ChemicalsBDH9230-2.5KGDextrose, anhydrous
Chemical compound, drugCitrateFisherScientificA104-500Citric acid, monohydrate
Chemical compound, drugGentamicinResearch Products InternationalG38000-10.0Gentamicin Sulfate
Chemical compound, drugNalidixic acidResearch Products InternationalN42000-25.0
Chemical compound, drugCarbinicillinGoldbioC-103–25Carbenicillin (Disodium)
Chemical compound, drugSucroseFisher BioReagentsBP220-212; 2.5 kgD-Sucrose
Chemical compound, drugHEPESSIGMAH3375-100Gbuffer
Chemical compound, drugTryptoneFisher BioreagentsBP1421-500LB
Chemical compound, drugNaCl; sodium chlorideFisher ChemicalS271-3LB
Chemical compound, drugYeast extractFisher BioreagentsBP1422-500LB
Chemical compound, drugAmmonium sulfateFisher ChemicalA702-500M63
Chemical compound, drugPotassium phosphate monobasicFisher ChemicalP382-500M63
Chemical compound, drugPotassium phosphate dibasic, anhydrousFisher ChemicalP288-500M63
Chemical compound, drugMagnesium SulfateFisher ScientificM63-500M63
Chemical compound, drugMilkBD232,100Difco Skim Milk
Chemical compound, drugYeast Nitrogen Base without amino acidsResearch Products InternationalY20040-500.0Yeast cloning
Chemical compound, drugYeast Synthetic Drop-out Medium Supplements without uracilSigmaY1501-20GYeast cloning
Chemical compound, drugPeptoneFisher bioreagentsBP1420-500YPD
Chemical compound, drugSodium phosphate dibasic anhydrousFisher ChemicalsS374-500ASM
Chemical compound, drugSodium phosphate monobasicFisher ChemicalsS369-500ASM
Chemical compound, drugPotassium NitrateFisher ChemicalsM-12636ASM
Chemical compound, drugPotassium SulfateFisher ChemicalsP304-500ASM
Chemical compound, drugL-(+)-Lactic acidSigmaL1750-10GASM; 1 M stock; pH to 7 with NaOH
Chemical compound, drugCalcium chloride dihydrateSigmaC7902-500GASM
Chemical compound, drugMagnesium Chloride HexahydrateFisher chemicalM33-500ASM
Chemical compound, drugFeSO4*7H2OSigma-AldrichF-8048ASM; Ferrous sulfate heptahydrate; Filter sterilized
Chemical compound, drugN-acetylglucosamineFisher ScientificAAA1304718ASM
Chemical compound, drugDPPCSigmaP0763-250MGASM; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine; dissolved in chloroform
Chemical compound, drugTryptophanSigma-AldrichT0254-25GASM, L-Tryptophan
Chemical compound, drugMucinSigmaM2378-100GASM; Mucin from porcine stomach, Type II
Peptide, recombinant proteinPhusionNew England BioLabsM0530LHigh-Fidelity DNA polymerase
Software, algorithmMATLABMathWorks
Software, algorithmbreseqPMID:24838886Version 0.35.4
Software, algorithmbcl2fastqIlluminaRRID:SCR_015058v2.20.0422
Software, algorithmGraphPad Prism 9GraphPadVersion 9.2.0

Data availability

All sequencing data is available on the Sequence Read Archive with accession number PRJNA786588 upon publication. All data generated or analyzed and all code used during this study are included in the manuscript or associated files.

The following data sets were generated
    1. Mould DL
    (2021) NCBI Sequence Read Archive
    ID PRJNA786588. Pool Seq of Experimentally Evolved P. aeruginosa PA14 populations in LB.

References

Article and author information

Author details

  1. Dallas L Mould

    Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, United States
    Contribution
    Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing - original draft, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6939-1351
  2. Mirjana Stevanovic

    Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, United States
    Contribution
    Formal analysis, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
  3. Alix Ashare

    1. Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, United States
    2. Department of Medicine, Dartmouth-Hitchock Medical Center, Lebanon, United States
    Contribution
    Funding acquisition, Resources, Writing – review and editing
    Competing interests
    No competing interests declared
  4. Daniel Schultz

    Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, United States
    Contribution
    Conceptualization, Formal analysis, Funding acquisition, Methodology, Supervision, Visualization, Writing – review and editing
    Competing interests
    No competing interests declared
  5. Deborah A Hogan

    Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, United States
    Contribution
    Conceptualization, Formal analysis, Funding acquisition, Project administration, Supervision, Validation, Writing – review and editing
    For correspondence
    dhogan@dartmouth.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6366-2971

Funding

Cystic Fibrosis Foundation (HOGAN19G0)

  • Dallas L Mould
  • Deborah A Hogan

Cystic Fibrosis Foundation (ASHARE20P0)

  • Alix Ashare

Cystic Fibrosis Foundation (STANTO19R0)

  • Daniel Schultz

Cystic Fibrosis Foundation (T32AI007519)

  • Dallas L Mould

National Institutes of Health (R01HL122372)

  • Alix Ashare

National Institutes of Health (GM130454)

  • Mirjana Stevanovic
  • Daniel Schultz

National Institutes of Health (P20GM113132)

  • Dallas L Mould
  • Deborah A Hogan

National Institutes of Health (DK117469)

  • Dallas L Mould
  • Alix Ashare
  • Daniel Schultz
  • Deborah A Hogan

National Institutes of Health (P30CA023108)

  • Dallas L Mould
  • Alix Ashare
  • Daniel Schultz
  • Deborah A Hogan

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

Research reported in this publication was supported by grants from the Cystic Fibrosis Foundation HOGAN19G0 (DAH), ASHARE20P0 (AA) and STANTO19R0 (DS), and the National Institutes of Health (NIH) through T32AI007519 (DLM), R01HL122372 (AA) and P20 GM130454-02 (DS). Additional core facility support came from the NIH NIGMS P20GM113132 (BioMT) and NIDDK P30-DK117469 (Dartmouth Cystic Fibrosis Research Center) and STANTO19R0 from the Cystic Fibrosis Foundation. Plasmid sequencing was carried out at Geisel School of Medicine Genomics Shared Resource, which was established by equipment grants from the NIH and NSF and is supported in part by a Cancer Center Core Grant (P30CA023108) from the NIH National Cancer Institute. We would like to acknowledge Amy Conaway for assistance in the kinase evolution screen, Dr. Georgia Doing for LasR colony enumeration in key experiments, and Dr. Nicholas Jacobs for constructive and thoughtful feedback on the written manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

© 2022, Mould et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,786
    views
  • 424
    downloads
  • 24
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Dallas L Mould
  2. Mirjana Stevanovic
  3. Alix Ashare
  4. Daniel Schultz
  5. Deborah A Hogan
(2022)
Metabolic basis for the evolution of a common pathogenic Pseudomonas aeruginosa variant
eLife 11:e76555.
https://doi.org/10.7554/eLife.76555

Share this article

https://doi.org/10.7554/eLife.76555

Further reading

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    Dániel Molnár, Éva Viola Surányi ... Judit Toth
    Research Article

    The sustained success of Mycobacterium tuberculosis as a pathogen arises from its ability to persist within macrophages for extended periods and its limited responsiveness to antibiotics. Furthermore, the high incidence of resistance to the few available antituberculosis drugs is a significant concern, especially since the driving forces of the emergence of drug resistance are not clear. Drug-resistant strains of Mycobacterium tuberculosis can emerge through de novo mutations, however, mycobacterial mutation rates are low. To unravel the effects of antibiotic pressure on genome stability, we determined the genetic variability, phenotypic tolerance, DNA repair system activation, and dNTP pool upon treatment with current antibiotics using Mycobacterium smegmatis. Whole-genome sequencing revealed no significant increase in mutation rates after prolonged exposure to first-line antibiotics. However, the phenotypic fluctuation assay indicated rapid adaptation to antibiotics mediated by non-genetic factors. The upregulation of DNA repair genes, measured using qPCR, suggests that genomic integrity may be maintained through the activation of specific DNA repair pathways. Our results, indicating that antibiotic exposure does not result in de novo adaptive mutagenesis under laboratory conditions, do not lend support to the model suggesting antibiotic resistance development through drug pressure-induced microevolution.

    1. Microbiology and Infectious Disease
    Linkang Wang, Haiyan Wang ... Ping Qian
    Research Article

    Bacillus velezensis is a species of Bacillus that has been widely investigated because of its broad-spectrum antimicrobial activity. However, most studies on B. velezensis have focused on the biocontrol of plant diseases, with few reports on antagonizing Salmonella Typhimurium infections. In this investigation, it was discovered that B. velezensis HBXN2020, which was isolated from healthy black pigs, possessed strong anti-stress and broad-spectrum antibacterial activity. Importantly, B. velezensis HBXN2020 did not cause any adverse side effects in mice when administered at various doses (1×107, 1×108, and 1×109 CFU) for 14 days. Supplementing B. velezensis HBXN2020 spores, either as a curative or preventive measure, dramatically reduced the levels of S. Typhimurium ATCC14028 in the mice’s feces, ileum, cecum, and colon, as well as the disease activity index (DAI), in a model of infection caused by this pathogen in mice. Additionally, supplementing B. velezensis HBXN2020 spores significantly regulated cytokine levels (Tnfa, Il1b, Il6, and Il10) and maintained the expression of tight junction proteins and mucin protein. Most importantly, adding B. velezensis HBXN2020 spores to the colonic microbiota improved its stability and increased the amount of beneficial bacteria (Lactobacillus and Akkermansia). All together, B. velezensis HBXN2020 can improve intestinal microbiota stability and barrier integrity and reduce inflammation to help treat infection by S. Typhimurium.